A hub of collaborative innovation, seeking development opportunities together - A record of Beijing Leite Pharmaceutical Technology Co., Ltd.'s participation in the 2025 Beijing Investment Conference
On the morning of March 28, 2025, the "2025 Investment Beijing Conference", jointly organized by the Beijing Municipal Government and jointly hosted by the Beijing Development and Reform Commission and the Beijing Investment Promotion Service Center, was grandly held in the Haihui Hall of the Zhongguancun International Innovation Center. As a representative of a key enterprise in Beijing's strategic emerging industries, Beijing Laite Pharmaceutical Technology Co., Ltd. was invited to attend this grand event.
This conference, with the theme "Invest in Beijing and Win the Future", focused on strategic emerging industries such as artificial intelligence, new-generation information technology, and medical health. Through various diversified forms including policy announcements, project signings, and industry promotions, it comprehensively showcased Beijing's innovative practices in building a modern industrial system and promoting high-level opening-up. The conference featured three core sections: "Meeting in Beijing", "Joining Hands with Beijing", and "Promoting Beijing". It focused on explaining Beijing's supportive policies for enterprises, government investment funds, and the development advantages of key parks.
Beijing Leite Pharmaceutical Company, as an invited participant, took part in this conference. During the meeting, the company's leaders carefully listened to the authoritative interpretation of the high-tech and cutting-edge industry policies by the Municipal Economic and Information Commission. They focused on the special support policies for the pharmaceutical sector, and the company leaders also signed contracts for major investment promotion projects at this conference.
As a pharmaceutical enterprise rooted in Miyun District, Beijing Laite Pharmaceutical has continuously increased its investment in innovation in recent years. The company's leadership stated after the meeting: "We will optimize our R&D strategic layout in accordance with policy guidance."
With the continuous advancement of Beijing's construction, the biopharmaceutical industry is entering a golden period of development. Beijing Laite Pharmaceutical Technology Co., Ltd. obtained the latest industry policy information through this conference. The enterprise stated that it will fully utilize the resource platform established by the conference to accelerate the industrialization process and contribute the enterprise's strength to the construction of Beijing as a global innovation hub for pharmaceutical and health industries.
